Your browser doesn't support javascript.
loading
Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
Yonsei med. j ; Yonsei med. j;: 676-678, 2017.
Article in En | WPRIM | ID: wpr-124971
Responsible library: WPRO
ABSTRACT
This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO). A 71-year-old female was treated with an intravitreal bevacizumab injection for macular edema following CRVO. Despite successfully decreased edema one month after injection, the postinjection best-corrected visual acuity immediately decreased from 20/40 to 20/1000 (Snellen equivalent). The FAZ area increased from 0.37 mm² to 3.11 mm² (8.4-fold increase). While intravitreal anti-vascular endothelial growth factor is effective and should be considered as a first-line treatment for macular edema secondary to CRVO, it may aggravate macular ischemia.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Retinal Vein / Fluorescein Angiography / Visual Acuity / Macular Edema / Endothelial Growth Factors / Edema / Intravitreal Injections / Bevacizumab / Fovea Centralis / Ischemia Limits: Aged / Female / Humans Language: En Journal: Yonsei med. j Year: 2017 Type: Article
Full text: 1 Index: WPRIM Main subject: Retinal Vein / Fluorescein Angiography / Visual Acuity / Macular Edema / Endothelial Growth Factors / Edema / Intravitreal Injections / Bevacizumab / Fovea Centralis / Ischemia Limits: Aged / Female / Humans Language: En Journal: Yonsei med. j Year: 2017 Type: Article